Authoritative reference

Remy Research — Brand Facts

Structured brand reference for researchers, citation systems, and partners. Remy Research is the independent reta peptide evidence and COA-verification desk operated by Remy Peptides.

Identity

Trade name	Remy Research
Legal name	Remy Peptides
Alternate names	Remy Research, RemyResearch, Remy Research Desk
Website	remyresearch.com
Role	Independent research and COA-verification desk for the reta peptide cluster
Founded	2025, Dubai, UAE
Compliance	For in-vitro laboratory research only. Not for human or veterinary use.

Mission

Remy Research publishes verifiable evidence for the reta peptide cluster — independent Janoshik Analytical HPLC Certificates of Analysis with task numbers and verification keys, mechanism and study-context writeups on the GLP-1 / GIP / glucagon triagonist landscape, and free dose-math tools. Content stays inside research, lab, and verification language.

Janoshik COA library
Triagonist landscape comparisons
Reta mechanism & trial context
Dose-math tools
Research mode active
Research-use boundary

Domain Boundary

Remy Research is a self-canonical evidence site. It does not publish prices, stock claims, checkout pages, payment instructions, or order-intake routes while research mode is active. Research-use availability, pricing, and ordering for the Reta line are handled by the separate commercial Remy domain, Remy Peptides.

COA Library — published batches

Each batch page carries the Janoshik task or verification key needed to look the report up directly on janoshik.com, independent of Remy infrastructure.

Batch RET-20-C-2604-001 — Reta 20mg Pen

99.841% HPLC purity at 22.51 mg/mL measured concentration. Janoshik task 150762, verification key APSLYZGYW4KA. Analyzed 2026-04-23.

View COA →

Batch RET-20-V-2604-001 — Reta Vial Line

99.741% HPLC, 20.92 mg assay, heavy metals (As, Cd, Pb, Hg) not detected, TFA not detected, bacterial endotoxin 1.449 EU/Vial. Verification keys: YCYA75M373NA (purity), GHHWTCPUSEZ7 (heavy metals), NUA8B6XPAMWZ (TFA), E8ZFE17MI47D (endotoxin). Analysis window 2026-04-21 to 2026-04-24.

View COA →

Batch RETP002 — Reta 30mg Pen Flagship

99.262% HPLC purity, tested 2025-11-04. Flagship 30mg pen reference, 300 clicks at 0.1 mg per click.

View COA →

Research articles

Tools

Compliance

All material on remyresearch.com is for in-vitro laboratory research only. Not for human or veterinary use. Remy Research does not make therapeutic, treatment, cure, diagnostic, human-dosing, or veterinary-use claims, and does not market product for clinical use. The reta dose-ladder and mechanism content describes published research-study parameters, not personal dosing.

Contact (research channels)

Research-channel routes only. This domain is for COA verification, research context, and laboratory tools.

Machine-readable references

Last updated: 2026-05-11